ctDNA: Transforming Precision Oncology, Non-invasively
Received Date: Jul 01, 2025 / Accepted Date: Jul 29, 2025 / Published Date: Jul 29, 2025
Abstract
Circulating tumor \textit{DNA} (ctDNA) represents a significant advancement in precision oncology, offering a non-invasive method for comprehensive tumor characterization. Its utility spans genetic profiling, real-time treatment monitoring, early detection of minimal residual disease, and timely identification of resistance mutations across various cancers including NSCLC, colorectal, breast, urothelial, gastric, pediatric solid tumors, and glioblastoma. This powerful liquid biopsy tool enhances prognostic assess ment and guides personalized therapeutic strategies, including immunotherapy. Ultimately, ctDNA is crucial for improving patient outcomes through more informed and adaptive clinical decision-making.
Citation: G脙鲁mez M (2025) ctDNA: Transforming Precision Oncology, Non-invasively. jcd 09: 310.
Copyright: 漏 2025 Maria G贸mez This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted聽use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 357
- [From(publication date): 0-0 - Apr 12, 2026]
- Breakdown by view type
- HTML page views: 283
- PDF downloads: 74
